Clinical Research Directory

Inclusion Criteria: * Patients with locally advanced (stage IIIb/IIIc), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not eligible for curative surgery and cannot undergo definitive radiotherapy/chemotherapy, according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer; * ALK-positive and the test results were based on RT-PCR /FISH /IHC /NGS methods in the laboratory department or testing institution of the hospital * receiving targeted therapy with Lorlatinib * age ≥18 years old * follow-up after receipt of Lorlatinib * voluntarily participate in the study and sign informed consent Exclusion Criteria: * evidence of any severe or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, active infections including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). * combined with other malignant tumors and received other anti-tumor therapy during the treatment of Lorlatinib